Granite Bay Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Granite Bay Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Buy	910 +8	+0.9%	+$3.73K	0.09%	60
2025 Q4	$409K	Buy	902 +2	+0.2%	+$862	0.1%	58
2025 Q3	$352K	Hold	900	–	–	0.09%	57
2025 Q2	$401K	Buy	900 +300	+50%	+$138K	0.13%	45
2025 Q1	$291K	Sell	600 -304	-34%	-$142K	0.1%	59
2024 Q4	$364K	Buy	904 +4	+0.4%	+$1.85K	0.13%	53
2024 Q3	$419K	Hold	900	–	–	0.24%	31
2024 Q2	$422K	Hold	900	–	–	0.23%	42
2024 Q1	$376K	Sell	900 -60,525	-99%	-$25.6M	0.21%	56
2023 Q4	$22.7M	Buy	61,425 +21,450	+54%	+$7.92M	0.2%	51
2023 Q3	$14M	Buy	39,975 +39,375	+6,563%	+$13.8M	0.14%	70
2023 Q2	$211K	Buy	+600	New	+$202K	0.2%	42
2022 Q2	–	Sell	-810	Closed	-$211K	–	62
2022 Q1	$211K	Sell	810 -190	-19%	-$45.1K	0.17%	58
2021 Q4	$220K	Buy	+1,000	New	+$194K	0.22%	57

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Granite Bay Wealth Management's VRTX Position: Q1 2026 in Review

Granite Bay Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.89% in Q1 2026, buying an estimated $3.73K and bringing the position to 910 shares worth $407K. The position accounts for 0.09% of the portfolio, ranked #60.

Granite Bay Wealth Management first reported a position in VRTX in Q4 2021 and has held it in 14 quarters since. The position peaked at $22.7M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Granite Bay Wealth Management held 910 shares of Vertex Pharmaceuticals worth $407K as of Q1 2026.
Granite Bay Wealth Management bought 8 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.73K.
Vertex Pharmaceuticals made up 0.09% of Granite Bay Wealth Management's portfolio in Q1 2026, its #60 holding.
Granite Bay Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
Granite Bay Wealth Management's Vertex Pharmaceuticals position peaked at $22.7M in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Granite Bay Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.